You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device
|
|---|---|
| Published in |
PLOS ONE, April 2012
|
| DOI | 10.1371/journal.pone.0035976 |
| Pubmed ID | |
| Authors |
Brian J. Kirby, Mona Jodari, Matthew S. Loftus, Gunjan Gakhar, Erica D. Pratt, Chantal Chanel-Vos, Jason P. Gleghorn, Steven M. Santana, He Liu, James P. Smith, Vicente N. Navarro, Scott T. Tagawa, Neil H. Bander, David M. Nanus, Paraskevi Giannakakou |
| Abstract |
Cancer metastasis accounts for the majority of cancer-related deaths owing to poor response to anticancer therapies. Molecular understanding of metastasis-associated drug resistance remains elusive due to the scarcity of available tumor tissue. Isolation of circulating tumor cells (CTCs) from the peripheral blood of patients has emerged as a valid alternative source of tumor tissue that can be subjected to molecular characterization. However, issues with low purity and sensitivity have impeded adoption to clinical practice. Here we report a novel method to capture and molecularly characterize CTCs isolated from castrate-resistant prostate cancer patients (CRPC) receiving taxane chemotherapy. We have developed a geometrically enhanced differential immunocapture (GEDI) microfluidic device that combines an anti-prostate specific membrane antigen (PSMA) antibody with a 3D geometry that captures CTCs while minimizing nonspecific leukocyte adhesion. Enumeration of GEDI-captured CTCs (defined as intact, nucleated PSMA+/CD45- cells) revealed a median of 54 cells per ml identified in CRPC patients versus 3 in healthy donors. Direct comparison with the commercially available CellSearch® revealed a 2-400 fold higher sensitivity achieved with the GEDI device. Confocal microscopy of patient-derived GEDI-captured CTCs identified the TMPRSS2:ERG fusion protein, while sequencing identified specific androgen receptor point mutation (T868A) in blood samples spiked with only 50 PC C4-2 cells. On-chip treatment of patient-derived CTCs with docetaxel and paclitaxel allowed monitoring of drug-target engagement by means of microtubule bundling. CTCs isolated from docetaxel-resistant CRPC patients did not show any evidence of drug activity. These measurements constitute the first functional assays of drug-target engagement in living circulating tumor cells and therefore have the potential to enable longitudinal monitoring of target response and inform the development of new anticancer agents. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 224 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 2% |
| Switzerland | 1 | <1% |
| Malaysia | 1 | <1% |
| France | 1 | <1% |
| Italy | 1 | <1% |
| Lithuania | 1 | <1% |
| Netherlands | 1 | <1% |
| Saudi Arabia | 1 | <1% |
| United Kingdom | 1 | <1% |
| Other | 2 | <1% |
| Unknown | 210 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 59 | 26% |
| Researcher | 33 | 15% |
| Student > Bachelor | 24 | 11% |
| Student > Master | 24 | 11% |
| Other | 14 | 6% |
| Other | 36 | 16% |
| Unknown | 34 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Engineering | 64 | 29% |
| Agricultural and Biological Sciences | 42 | 19% |
| Medicine and Dentistry | 31 | 14% |
| Biochemistry, Genetics and Molecular Biology | 23 | 10% |
| Chemistry | 11 | 5% |
| Other | 14 | 6% |
| Unknown | 39 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2023.
All research outputs
#1,620,515
of 23,575,346 outputs
Outputs from PLOS ONE
#20,654
of 201,789 outputs
Outputs of similar age
#9,654
of 164,949 outputs
Outputs of similar age from PLOS ONE
#329
of 3,702 outputs
Altmetric has tracked 23,575,346 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 201,789 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,949 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 3,702 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.